It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Independent scientific achievements have led to the discovery of aberrant splicing patterns in oncogenesis, while more recent advances have uncovered novel gene fusions involving neurotrophic tyrosine receptor kinases (NTRKs) in gliomas. The exploration of NTRK splice variants in normal and neoplastic brain provides an intersection of these two rapidly evolving fields. Tropomyosin receptor kinase B (TrkB), encoded NTRK2, is known for critical roles in neuronal survival, differentiation, molecular properties associated with memory, and exhibits intricate splicing patterns and post-translational modifications. Here, we show a role for a truncated NTRK2 splice variant, TrkB.T1, in human glioma. TrkB.T1 enhances PDGF-driven gliomas in vivo, augments PDGF-induced Akt and STAT3 signaling in vitro, while next generation sequencing broadly implicates TrkB.T1 in the PI3K signaling cascades in a ligand-independent fashion. These TrkB.T1 findings highlight the importance of expanding upon whole gene and gene fusion analyses to include splice variants in basic and translational neuro-oncology research.
Tropomyosin receptor kinase B (TrkB), encoded by the neurotrophic tyrosine receptor kinase 2 (NTRK2) gene, exhibits intricate splicing patterns and post-translational modifications. Here, the authors perform whole gene and transcript-level analyses and report the TrkB.T1 splice variant enhances PDGF-driven gliomas in vivo and augments PI3K signaling cascades in vitro.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Arora Sonali 1 ; Cimino, Patrick J 2
; Ozawa Tatsuya 3 ; Szulzewsky Frank 1
; Hoellerbauer Pia 4 ; Bonifert Tobias 1 ; Hoffstrom, Benjamin G 5 ; Boiani, Norman E 5 ; Bolouri Hamid 6 ; Correnti, Colin E 7 ; Oldrini, Barbara 8 ; Silber, John R 9 ; Squatrito Massimo 8
; Paddison, Patrick J 4 ; Holland, Eric C 10
1 Fred Hutchinson Cancer Research Center, Human Biology Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
2 Fred Hutchinson Cancer Research Center, Human Biology Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); University of Washington School of Medicine, Department of Pathology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
3 National Cancer Center Research Institute, Division of Brain Tumor Translational Research, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385)
4 Fred Hutchinson Cancer Research Center, Human Biology Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); University of Washington, Molecular and Cellular Biology Program, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
5 Fred Hutchinson Cancer Research Center, Antibody Technology Resource, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
6 Fred Hutchinson Cancer Research Center, Human Biology Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, USA (GRID:grid.416879.5) (ISNI:0000 0001 2219 0587)
7 Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
8 Spanish National Cancer Research Centre, Seve Ballesteros Foundation Brain Tumor Group, Madrid, Spain (GRID:grid.7719.8) (ISNI:0000 0000 8700 1153)
9 University of Washington School of Medicine, Department of Neurological Surgery, Alvord Brain Tumor Center, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
10 Fred Hutchinson Cancer Research Center, Human Biology Division, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622); University of Washington School of Medicine, Department of Neurological Surgery, Alvord Brain Tumor Center, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); Seattle Tumor Translational Research Center, Fred Hutchinson Cancer Research Center, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)




